Summary:

The Fc domain plays a critical role in modulating the efficacy, safety, and pharmacology of antibody-based therapeutics and vaccines. Yet, most development pipelines assess only a narrow subset of Fc-mediated effector functions, risking missed opportunities and avoidable liabilities. In this presentation, Dr. Shashi Jatiani highlights how SeromYx’s high-throughput, physiologically relevant Fc profiling platform enables comprehensive evaluation of antibody function early in development.

Featuring case studies across mAbs, Fc-engineered variants - including clinical-stage and marketed antibodies, and other formats, the talk illustrates how expanded Fc profiling can inform lead selection, support mechanism-of-action studies, and derisk engineering strategies with clinical relevance.

Key Highlights:

• Comprehensive Fc Profiling Enables Functional Characterization Beyond ADCC/ADCP: Expanded assessment of effector functions such as ADNP, ADEP, and complement activation uncovers mechanistic insights missed by conventional approaches.

• Fc Engineering and Conjugation Strategies Require Functional Validation: Case studies demonstrate how antigen-specific FcγR binding and functional assays reveal unintended impacts of Fc silencing, half-life extension, and CAR-T conjugation methods.

• Fab-Fc Interplay Influences Functional Potency: Data from large antibody libraries show that Fc function varies substantially across mAbs with identical Fc domains, emphasizing the need to assess effector activity alongside Fab affinity in lead optimization.